Literature DB >> 24132240

SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients.

Aleksandr Shcheglovitov1, Olesya Shcheglovitova, Masayuki Yazawa, Thomas Portmann, Rui Shu, Vittorio Sebastiano, Anna Krawisz, Wendy Froehlich, Jonathan A Bernstein, Joachim F Hallmayer, Ricardo E Dolmetsch.   

Abstract

Phelan-McDermid syndrome (PMDS) is a complex neurodevelopmental disorder characterized by global developmental delay, severely impaired speech, intellectual disability, and an increased risk of autism spectrum disorders (ASDs). PMDS is caused by heterozygous deletions of chromosome 22q13.3. Among the genes in the deleted region is SHANK3, which encodes a protein in the postsynaptic density (PSD). Rare mutations in SHANK3 have been associated with idiopathic ASDs, non-syndromic intellectual disability, and schizophrenia. Although SHANK3 is considered to be the most likely candidate gene for the neurological abnormalities in PMDS patients, the cellular and molecular phenotypes associated with this syndrome in human neurons are unknown. We generated induced pluripotent stem (iPS) cells from individuals with PMDS and autism and used them to produce functional neurons. We show that PMDS neurons have reduced SHANK3 expression and major defects in excitatory, but not inhibitory, synaptic transmission. Excitatory synaptic transmission in PMDS neurons can be corrected by restoring SHANK3 expression or by treating neurons with insulin-like growth factor 1 (IGF1). IGF1 treatment promotes formation of mature excitatory synapses that lack SHANK3 but contain PSD95 and N-methyl-D-aspartate (NMDA) receptors with fast deactivation kinetics. Our findings provide direct evidence for a disruption in the ratio of cellular excitation and inhibition in PMDS neurons, and point to a molecular pathway that can be recruited to restore it.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24132240      PMCID: PMC5559273          DOI: 10.1038/nature12618

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  32 in total

1.  Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo.

Authors:  Tanjew Dittgen; Axel Nimmerjahn; Shoji Komai; Pawel Licznerski; Jack Waters; Troy W Margrie; Fritjof Helmchen; Winfried Denk; Michael Brecht; Pavel Osten
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-17       Impact factor: 11.205

2.  Generation of cortical neurons from mouse embryonic stem cells.

Authors:  Nicolas Gaspard; Tristan Bouschet; Adèle Herpoel; Gilles Naeije; Jelle van den Ameele; Pierre Vanderhaeghen
Journal:  Nat Protoc       Date:  2009-09-17       Impact factor: 13.491

3.  Rapid bidirectional switching of synaptic NMDA receptors.

Authors:  Camilla Bellone; Roger A Nicoll
Journal:  Neuron       Date:  2007-09-06       Impact factor: 17.173

4.  De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia.

Authors:  Julie Gauthier; Nathalie Champagne; Ronald G Lafrenière; Lan Xiong; Dan Spiegelman; Edna Brustein; Mathieu Lapointe; Huashan Peng; Mélanie Côté; Anne Noreau; Fadi F Hamdan; Anjené M Addington; Judith L Rapoport; Lynn E Delisi; Marie-Odile Krebs; Ridha Joober; Ferid Fathalli; Fayçal Mouaffak; Ali P Haghighi; Christian Néri; Marie-Pierre Dubé; Mark E Samuels; Claude Marineau; Eric A Stone; Philip Awadalla; Philip A Barker; Salvatore Carbonetto; Pierre Drapeau; Guy A Rouleau
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

5.  Novel de novo SHANK3 mutation in autistic patients.

Authors:  Julie Gauthier; Dan Spiegelman; Amélie Piton; Ronald G Lafrenière; Sandra Laurent; Judith St-Onge; Line Lapointe; Fadi F Hamdan; Patrick Cossette; Laurent Mottron; Eric Fombonne; Ridha Joober; Claude Marineau; Pierre Drapeau; Guy A Rouleau
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-04-05       Impact factor: 3.568

6.  Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice.

Authors:  Daniela Tropea; Emanuela Giacometti; Nathan R Wilson; Caroline Beard; Cortina McCurry; Dong Dong Fu; Ruth Flannery; Rudolf Jaenisch; Mriganka Sur
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-10       Impact factor: 11.205

7.  Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms.

Authors:  H L Wilson; A C C Wong; S R Shaw; W-Y Tse; G A Stapleton; M C Phelan; S Hu; J Marshall; H E McDermid
Journal:  J Med Genet       Date:  2003-08       Impact factor: 6.318

8.  Shank3 mutant mice display autistic-like behaviours and striatal dysfunction.

Authors:  João Peça; Cátia Feliciano; Jonathan T Ting; Wenting Wang; Michael F Wells; Talaignair N Venkatraman; Christopher D Lascola; Zhanyan Fu; Guoping Feng
Journal:  Nature       Date:  2011-03-20       Impact factor: 49.962

9.  Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication.

Authors:  Ozlem Bozdagi; Takeshi Sakurai; Danae Papapetrou; Xiaobin Wang; Dara L Dickstein; Nagahide Takahashi; Yuji Kajiwara; Mu Yang; Adam M Katz; Maria Luisa Scattoni; Mark J Harris; Roheeni Saxena; Jill L Silverman; Jacqueline N Crawley; Qiang Zhou; Patrick R Hof; Joseph D Buxbaum
Journal:  Mol Autism       Date:  2010-12-17       Impact factor: 7.509

10.  A critical role for IGF-II in memory consolidation and enhancement.

Authors:  Dillon Y Chen; Sarah A Stern; Ana Garcia-Osta; Bernadette Saunier-Rebori; Gabriella Pollonini; Dhananjay Bambah-Mukku; Robert D Blitzer; Cristina M Alberini
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

View more
  212 in total

Review 1.  Concise Review: Exciting Cells: Modeling Genetic Epilepsies with Patient-Derived Induced Pluripotent Stem Cells.

Authors:  Andrew M Tidball; Jack M Parent
Journal:  Stem Cells       Date:  2015-09-15       Impact factor: 6.277

Review 2.  Direct somatic lineage conversion.

Authors:  Koji Tanabe; Daniel Haag; Marius Wernig
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-10-19       Impact factor: 6.237

Review 3.  Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders.

Authors:  Mustafa Sahin; Mriganka Sur
Journal:  Science       Date:  2015-10-15       Impact factor: 47.728

Review 4.  From the genetic architecture to synaptic plasticity in autism spectrum disorder.

Authors:  Thomas Bourgeron
Journal:  Nat Rev Neurosci       Date:  2015-09       Impact factor: 34.870

Review 5.  Induced pluripotent stem cells for modeling neurological disorders.

Authors:  Fabiele B Russo; Fernanda R Cugola; Isabella R Fernandes; Graciela C Pignatari; Patricia C B Beltrão-Braga
Journal:  World J Transplant       Date:  2015-12-24

6.  Micro-electrode array recordings reveal reductions in both excitation and inhibition in cultured cortical neuron networks lacking Shank3.

Authors:  C Lu; Q Chen; T Zhou; D Bozic; Z Fu; J Q Pan; G Feng
Journal:  Mol Psychiatry       Date:  2015-11-24       Impact factor: 15.992

Review 7.  The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.

Authors:  Jesse Costales; Alexander Kolevzon
Journal:  Neurosci Biobehav Rev       Date:  2016-01-15       Impact factor: 8.989

Review 8.  Using Patient-Derived Induced Pluripotent Stem Cells to Model and Treat Epilepsies.

Authors:  Xixi Du; Jack M Parent
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

9.  Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice.

Authors:  Adam B Steinmetz; Sarah A Stern; Amy S Kohtz; Giannina Descalzi; Cristina M Alberini
Journal:  J Neurosci       Date:  2017-12-07       Impact factor: 6.167

10.  Predicting the functional states of human iPSC-derived neurons with single-cell RNA-seq and electrophysiology.

Authors:  C Bardy; M van den Hurk; B Kakaradov; J A Erwin; B N Jaeger; R V Hernandez; T Eames; A A Paucar; M Gorris; C Marchand; R Jappelli; J Barron; A K Bryant; M Kellogg; R S Lasken; B P F Rutten; H W M Steinbusch; G W Yeo; F H Gage
Journal:  Mol Psychiatry       Date:  2016-10-04       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.